Are Propaten-Bonded PTFE Arterial Grafts Cost Effective: How Well Does Their Improved Patency Persist


Dept. of Cardiovascular and Thoracic Surgery, Odense University Hospital, Denmark
Dept. of Cardiovascular and Thoracic Surgery, Aalborg Hospital, Denmark
Dept. of Cardiovascular and Thoracic Surgery, Kolding Hospital, Denmark
Dept. of Cardiovascular and Thoracic Surgery, Eksjö District Hospital, Sweden
Dept. of Cardiovascular and Thoracic Surgery, Stavanger University Hospital, Norway
Dept. of Cardiovascular and Thoracic Surgery, Oslo University Hospital, Aker, Norway
Dept. of Cardiovascular and Thoracic Surgery, Haukeland University Hospital, Norway
Dept. of Cardiovascular and Thoracic Surgery, Rigshospitalet, Denmark
Vascular Research Unit, Viborg hospital, Denmark

Disclosures

Gore sponsored an annual trial meeting and equalised costs of grafts
After positive results appeared Lindholt and Ravn have given Gore-sponsored presentations of the Propaten trial

Multicentre randomised clinical controlled trial testing Propaten vs standard ePTFE

Planned femoropopliteal or femorofemoral crossover bypasses due to functional or critical chronically ischaemia
• 90% power: 484 participants
  • all + 5 years observation
• Follow up by duplex ultrasound scanning and medical record review
• Costs estimated using national diagnosis related grouping tariffs (DRG) + cost difference of grafts
• Assumption: a patent graft increases Qol by 25%*


Add. costs

Add. Patent years: 25.15 years
Add. cost: $1192/Propaten graft
$52977 per gained QALY

Add. costs

Add. Patent years: 74.44 years
Add. cost: $144/PTFE graft
$684 per gained QALY

Add. costs

Add. Patent years: 58.35 years
Add. cost: $2367/Propaten graft
$5491 per gained QALY

Add. costs

Add. Patent years: 33.17 years
Add. cost: $3400/Propaten graft
$22.296 per gained QALY

Fem-X-bypasses – Final primary patency

Critical ischemia

Intermittent claudication

Critical ischemia – 5 year primary patency

Add. costs

Add. Patent years: 58.35 years
Add. cost: $2367/Propaten graft
$5491 per gained QALY

Add. costs

Add. Patent years: 33.17 years
Add. cost: $3400/Propaten graft
$22.296 per gained QALY

Add. costs

Add. Patent years: 74.44 years
Add. cost: $144/PTFE graft
$684 per gained QALY

Add. costs

Add. Patent years: 25.15 years
Add. cost: $1192/Propaten graft
$52977 per gained QALY

Add. costs

Add. Patent years: 58.35 years
Add. cost: $2367/Propaten graft
$5491 per gained QALY

Add. costs

Add. Patent years: 33.17 years
Add. cost: $3400/Propaten graft
$22.296 per gained QALY
Conclusions

- In critical ischemia, propaten reduces the risk of losing primary patency by 40-50% the first 5 years in a cost effective way.

- In general, a "catch up" is noticed after 5-6 years.

- Primary patency significantly improved overall survival and increased time at risk for additional procedures and related costs – so does Propaten tend to do.